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Abstract The fibroblast growth factor receptors (FGFRs)
regulate important biological processes including cell
proliferation and differentiation during development and
tissue repair. Over the past decades, numerous pathological
conditions and developmental syndromes have emerged as
a consequence of deregulation in the FGFRs signaling
network. This review aims to provide an overview of
FGFR family, their complex signaling pathways in
tumorigenesis, and the current development and applica-
tion of therapeutics targeting the FGFRs signaling for
treatment of refractory human cancers.
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Cancer  Signal transduction  Targeted therapy
Introduction
The human fibroblast growth factor receptor (FGFR)
family, a subfamily of receptor tyrosine kinases (RTKs),
comprises of four family members—FGFR1, FGFR2,
FGFR3 and FGFR4. A closely-related receptor which lacks
the FGF signaling tyrosine kinase domain, FGFR5, (also
known as FGFRL1) was recently discovered on the basis of
interaction with FGFR-binding ligands, known as fibroblast
growth factors (FGFs) [1]. Collectively, FGFR signaling is
associated with the activation of multiple cellular cascades
and responses such as cell growth, proliferation, differen-
tiation, and survival [2–4].
FGFR protein structures
The FGFR family members share a high percentage of
sequence homology (*55–72 %) [5], and consist of three
important domains—extracellular ligand-binding domain,
single transmembrane domain, and intracellular tyrosine
kinase domain (Fig. 1). The extracellular ligand binding-
domain comprises of a hydrophobic signal peptide region
and two or three immunoglobulin (Ig)-like domains, des-
ignated D1–D3. The acid box is made up of *30 serine
residues and connects D1 and D2. The transmembrane
domain facilitates signal transduction from the extracellu-
lar region into the cytoplasmic domain. Emerging from the
cytoplasmic membrane is a juxtamembrane region, fol-
lowed by a split tyrosine kinase domain, and finally a
COOH tail [2, 5, 6].
Although FGFR5 is structurally similar to other FGFRs,
it lacks the intracellular protein tyrosine kinase domain,
which is replaced by a short intracellular tail with a histi-
dine-rich motif [1]. Due to the absence of the tyrosine
kinase domain, FGFR5 cannot signal by transautophosph-
orylation (as other FGFRs), and hence does not function
like other FGFRs. Instead, FGFR5 is proposed to act as
decoy receptor that binds FGF ligands and sequesters them
away from the conventional FGFRs [1]. Additionally, the
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signal peptide found within the extracellular ligand bind-
ing-domain is cleaved off upon insertion into the endo-
plasmic reticulum, and FGFR5 is occasionally shed from
the plasma membrane and is found in a secreted, soluble
form [1]. FGFR5 binds to certain FGFs, as do the con-
ventional FGFRs, but it does not bind to FGF1, which is
also recognized by all of the other FGFRs [1].
Alternative splicing of FGFRs
Despite the general characteristics shared among the family
members of FGFRs, an array of isoforms exist within each
family member (Fig. 2). Structural diversity observed
across the isoforms of FGFRs, is largely attributed to the
alternative splicing of endogenous mRNA sequence. These
isoforms include the secreted form of FGFRs that lack the
hydrophobic membrane-spanning region and the entire
cytoplasmic catalytic domain [7, 8], FGFRs with an
extracellular domain composed of either two or three Ig-
like domains [7, 9–11], and FGFRs devoid of the acid box
[12].
One of the most important mechanisms that determine
the ligand-binding specificity of FGFRs is by alternate
exon usage of the IgIII (D3) domain to produce three
possible IgIII domains isoforms, designated IgIIIa, IgIIIb
and IgIIIc. IgIIIa is encoded entirely by exon 7 alone while
IgIIIb and IgIIIc are derived from alternative splicing of
exon 7/8 and exon 7/9, respectively (Fig. 2) [13–16]. The
IgIIIb and IgIIIc splice variants are commonly observed in
FGFR1, FGFR2 and FGFR3 gene [13, 17]. The FGFR4
gene is unique as only IgIIIc variants are present [18].
Ig-like Domain I (D1)
Ig-like Domain II (D2)







Fig. 1 The basic structure of a FGFR. The FGFRs are phylogenet-
ically closely related to the VEGFRs and PDGFRs, consist of three
extracellular immunoglobulin (Ig) domains (D1-D3), a single trans-
membrane helix, an intracellular split tyrosine kinase domain (TK1
and TK2) and an acidic box. D2 and D3 form the ligand-binding
pocket and have distinct domains that bind both FGFs and heparan
sulfate proteoglycans (HSPGs). Acidic box is required for binding of
bivalent cations for optimal interaction between FGFRs and HSPGs
Fig. 2 FGFR splice variants. The FGFRs isoforms are generated
mainly by alternative splicing of the Ig III domain (D3). The D3 could
be encoded by an invariant exon 7 (red) to produce FGFR-IIIa isofom
or spliced to either exon 8 (green) or 9 (yellow) to generate the FGFR-
IIIb or FGFR-IIIc isoforms, respectively. Epithelial tissues predom-
inantly express the IIIb isoform and mesenchymal tissues express IIIc.
FGFR4 is expressed as a single isoform that is paralogous to FGFR-
IIIc. Hatched box represents a truncated carboxyl terminal. Clear box
indicates a deletion of an exon
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FGFR5 isoforms lacking the sequences that encode for
either the first Ig domain or the first Ig domain plus the
acidic box were also identified, but the properties of these
isoforms are not known and no tissue-specific expression
has yet been reported [1].
Activation and signaling of FGFR
FGFR signaling is primarily triggered by the binding of the
receptors to FGF ligands (Table 1), and the subsequent
formation of various complexes to initiate downstream
signal transduction including activation of PLCc, MAPK,
AKT, and STAT cascade (Fig. 3) [19].
The phosphotyrosine residues in the carboxy-terminal
regions of FGFR confer selective and strong binding to Src
homolog 2 (SH2) domain-containing molecules, such as
phospholipase Cc (PLCc) [20, 21]. This interaction results
in the hydrolysis of phosphatidylinositol 4,5-biphosphate
(PIP2) to generate two effectors, inositol 1,4,5-triphosphate
(IP3) and diacylglycerol (DAG) [22]. Accumulation of IP3
further stimulates calcium release from internal stores,
whereas DAG mediates the activation of protein kinase C
(PKC) and other downstream targets such as the Ras/MEK/
MAPK pathway (Fig. 3) [22].
One of the many adaptor proteins which facilitates
signal transduction from FGFRs is the v-crk sarcoma virus
CT10 oncogene homolog (avian) (Crk). Upon exposure to
growth factors, the juxtamembrane tyrosine residue 463 of
FGFR1 is phosphorylated, followed by the transient
phosphorylation of Crk to mediate the co-complexing of



























































Fig. 3 FGFR signaling pathway. FGFs induce FGFR-mediated
signaling pathway by interacting with specific FGFRs and HSPGs.
The macromolecular interactions mediate FGFRs dimerization or
oligomerization and activate multiple signal transduction pathways,
including those involving FRS2, RAS, p38 MAPKs, ERKs, JNKs,
Src, PLCc, Crk, PKC and PI3K. These pathways are negatively
regulated in part by the activities of DUSPs, SPRY, SEF and CBL
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with various signaling molecules such as the guanine
nucleotide exchange factor, SOS [24] and C3G [25], as
well as the dedicator of cytokinesis 1 (DOCK1) [26]. SOS
then activates JNK via Ras [27] and Rac [28, 29]. In
addition to Rac, cdc42 has also been proposed as an
intermediate to the JNK and p38 activation cascades [27].
Direct interaction of DOCK180 to Rac1 have been repor-
ted, and DOCK180 activates JNK in a manner dependent
on Cdc42Hs, and SEK [30]. On the other hand, C3G
activates JNK1 through a pathway involving the MLK
family of protein [31].
Activation of FGFRs also lead to phosphorylation of the
docking protein FGFR substrate 2 (FRS2) followed by the
recruitment of Shp2 tyrosine phosphatase, whereby the
subsequent phosphorylation of Shp2 facilitates its associ-
ation with growth factor receptor-bound 2 (Grb2) and SOS
[32–35]. This complex triggers the induction of the Ras/
MEK/MAPK signaling pathway [32]. In addition, the
tyrosine phosphorylation of FRS2a also mediates the
recruitment of Grb2 and Gab1, resulting in the recruitment
and activation of PI3-kinase [36]. Alternatively, the Grb2/
FRS2a complex interacts with Cbl via the SH3 domains
resulting in the ubiquitination of FGFRs and FRS2a for the
attenuation of growth factor signaling [37].
Accessory proteins such as SH2 domain-containing
adaptor protein B (Shb) and SH2 domain-containing col-
lagen (Shc) also interact with FGFRs to facilitate signal
transduction [22, 38–43]. Shb2 binds to tyrosine 766 in
FGFR1 to facilitate the phosphorylation of FRS2 for the
subsequent activation of the Ras/MEK/MAPK pathway
[22]. Similar to Shp2, Shc is an intermediate molecule
which mediates the assembly of FGFR and Grb2-SOS
complexes, also to activate the Ras/Raf/MEK/MAPK
pathway [3, 41, 44]. Shc co-localizes exclusively with
FGFR2 at the plasma membrane and intracellular mem-
branous compartment [45]. The localization of Shc and the
stabilization of the binding of its SH2 domain to FGFR2 is
attributed to the presence of the phosphotyrosine-binding
(PTB) domain [45, 46].
FGFR also binds to signal transducers and activators of
transcription (STAT) and ribosomal protein S6 kinase 2
(RSK2). The interaction between FGFR and STAT was
first observed in polymorphism studies, in which the point
mutation—K650E of FGFR3, and other FGFR isoforms,
led to the constitutive activation of both FGFR and STAT
[47–49]. STAT3 was further documented to bind to phos-
phorylated Tyr677 of FGFR1 [50]. In addition, tyrosine
activation of STAT3 requires the overexpression of FGFR1
or FGFR2 (Fig. 3) [50].
Negative regulation of FGFR signaling
Given the fact that FGFRs activate an array of signaling
pathways, it is crucial to have a regulatory system in place
to circumvent unnecessary signal transmission. FGF sig-
naling is negatively modulated by regulators such as Cbl
proto-oncogene E3 ubiquitin protein ligase (CBL), sprouty
homolog (SPRY), similar expression to fgf genes (SEF)
and MAPK phosphatases (MKP) (Fig. 3).
Following activation, FGFRs are often ubiquitinated by
CBL to facilitate clathrin-mediated endocytosis and
receptor degradation [37, 51]. Intriguingly, different FGFR
isoforms have discrete propensities for ubiquitination.
FGFR1 is more susceptible to ubiquitination whereas
FGFR4 has only a few lysine ubiquitination sites [52, 53].
The difference in ubiquitination is thought to account for
the different sorting of FGFRs to the lysosome [52].
A second pathway that negatively regulates FGFR sig-
naling involves the inhibition of RAS/RAF/ERK down-
stream pathway through SPRY [54–59]. Upon FGF ligand
stimulation, SPRY isoforms form homo- and hetero-olig-
omers via their C-terminal domains and attenuate ERK
activation through interaction with FRS2–Grb2-SOS
complex or direct inhibition of RAS/RAF signaling path-
way (Fig. 3) [56, 60–64]. Among all the SPRY isoforms,
SPRY2 is considered more inhibitory than SPRY1 and
SPRY 4 [61], but the SPRY1/SPRY4 hetero-oligomer
exhibits the most potent inhibitory effect on ERK [60].
However, the binding of SPRYs to Grb2 does not always
result in ERK inhibition [65, 66]. This implies that SPRY
can inhibit signal transduction in a Grb2-independent
pathway, and the molecular machinery that is involved in
this context is worth investigating. In this context, it is
likely that the functional role of SPRY in FGFR signaling
is highly dependent on the cell type and stimuli, and might
play a different role in different cell types.
In addition to CBL and SPRY, SEF has also been shown
to negatively modulates FGF-mediated ERK and AKT
activation [67–70]. In addition to receptor inhibition, SEF
could also hinder the nuclear translocation of ERK in
certain cell lines (Fig. 3) [71, 72].
Table 1 Ligand specificity of the fibroblast growth factor receptor
family [188–201]
FGFR isoform Ligand specificity
FGFR1, IIIb FGF-1, 2, 3, 10, and 22
FGFR1, IIIc FGF-1, 2, 4, 5, 6, 19, 20, and 21
FGFR2, IIIb FGF-1, 3, 4, 6, 7, 10, and 22
FGFR2, IIIc FGF-1, 2, 4, 5, 6, 8, 9, 17, 18, 19, 21, and 23
FGFR3, IIIb FGF-1 and 9
FGFR3, IIIc FGF-1, 2, 4, 8, 9, 17, 18 19, 21, and 23
FGFR4 FGF-1, 2, 4, 6, 8, 9, 16, 17, 18, and 19
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The role of dual phosphatases in the negative feedback
of growth factor signaling has also been reported by many
researches. For instance, the MAP kinase phosphatase -1
(MKP-1) has been discovered on the basis of its ability to
dephosphorylate MAP kinase in vivo [73]. Similarly,
MKP-3 blocks both the phosphorylation and enzymatic
activation of ERK2 by mitogens [74]. Consistent with this,
the targeted inactivation of Dusp6, which encodes MKP-3,
led to the increase of phosphorylated ERK and pERK
targets [75]. However, not every member of this class of
dual phosphatase inhibits ERK. Although MKP-3 blocks
ERK1 activation by oncogenic p21(ras), but ERK1 acti-
vated by p21(ras) (G12V) is insensitive to the M3/6 dual
phosphatase [76].
FGFRs and human cancer
Numerous human pathological conditions are tightly
associated with the deregulation of FGFR signaling.
Aberrant FGFR signaling is largely attributed to several
underlying mechanisms involving gene amplification, sin-
gle nucleotide polymorphism (SNP), chromosomal trans-
location, ligand availability and impaired termination
program in FGF-mediated signaling, which is reviewed in
the following section. In addition, a further layer of com-
plexity is added by the fact that FGFRs are subjected to
alternative splicing, giving rise to multiple isoforms which
may promote or repress tumorigenesis, under different
circumstances.
Gene amplification
Enhanced FGFR expression is commonly observed in
various types of human malignancies. Such elevations in
FGFRs expression could be due to gene amplification or
deregulation at the transcriptional level (Table 2) [77–80].
In line with this, the chromosomal regions 8p11-12 and
10q26 are consistently amplified in human breast cancers,
and some of the genes within this region that are amplified
are FGFR1 and FGFR2 [77–83]. Amplifications of 8p11
and 8p12 are associated with early relapse, poor prognosis
and survival, especially in ER-positive breast cancer
patients where FGFR1 amplification drives resistance to
hormonal therapy [84–86]. Although high copy numbers
and expression levels of FGFR1 has been shown to pro-
mote tumorigenesis [79, 87–90], several studies also show
that amplification of the focal region 8p11-12 does not
always result in the overexpression of FGFR1 [91–93]. In
this case, other genes located at the same locus may also be
amplified and contribute to the oncogenesis of human
mammary carcinomas [92], independent of FGFR1.
Indeed, a few candidate genes identified from the recurrent
amplicon 8p11-12 were overexpressed and promotes the
survival of the breast tumors [93].
Amplification of the FGFR2 gene is identified in gastric,
lung, and endometrial primary tumors and biologically-
transformed cell lines [19, 78, 80, 82, 83, 94–102]. Fur-
thermore, this event is occasionally accompanied by other
forms of genetic alteration such as base deletion. For
example, scirrhous-type gastric cancer cells which harbor
amplification in the region 10q26, were also found to
contain deletions in the C terminal of the FGFR2 exons
[103]. It is postulated that the presence of highly amplified
copies of the truncated receptor could promote tumor
proliferation and oncogenesis [104–106].
It is also common to observe secondary chromosomal
locus amplification in parallel to elevated FGFR expres-
sion. For instance, 30–40 % of breast tumors with ampli-
fication of the FGFR1-containing chromosomal region
8p12, were concurrently presented with CCND1 (Cyclin
D1) gene amplification at the 11q13 locus [77]. Since the
number of genetic alterations observed in tumor is asso-
ciated with poor prognosis [107], there could be a syner-
gistic effect from the concomitant amplification of both
oncogenes to drive tumorigenesis.
Point mutations
Various human diseases are driven, in part, by point
mutations. The sequencing of cancer genomes has uncov-
ered over a thousand somatic mutations in the coding exons
of 518 human kinase genes [108]. Most of the non-syn-
onymous mutations involve FGF signaling [108]. Onco-
genic point mutations of FGFRs could essentially include
any parts of the receptor, as summarized in Table 3. Some
of these mutations have been shown to exert a gain-of-
function effect, contributing to the developmental abnor-
malities, uncontrolled growth, and metastasis in a various
cancerous cells, the role of other mutations in tumorigen-
esis remained unknown [108].
Various hotspots for point mutations have been char-
acterized in FGFR2. Substitution of S252W and P253R
alter the ligand binding specificities of FGFR2b and
FGFR2c, but retain the ligand-dependent activation
Table 2 Gene amplifications of FGFRs in human cancers
FGFRs Cancer types References




FGFR2 Gastric, breast, lung, endometrial
and esophageal cancer
[78, 80, 82, 95–102,
207–211]
FGFR3 Bladder and salivary adenoid cystic
cancer
[212, 213]
FGFR4 Gastric, breast and ovarian cancer [80, 83, 94, 214]
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properties [109], whereas K659N causes receptor hyper-
activation [110]. In terms of disease pathogenesis, point
mutations of S252W and P253R in FGFR2 are associated
with Apert syndrome [111], and some of these led to a
crouzonoid phenotype [111–114]. Similar point mutations
were also observed in various cancer types, such as uterine
Table 3 Point mutations of
FGFRs in human cancers
a Mutations relative to the FGFR1
IIIc (GenBank accession number
NM_023110)
b Mutations relative to the FGFR2
IIIc (GenBank accession number
NP_000132)
c Mutations relative to the FGFR3
IIIc (GenBank accession number
NP_000133)
d Mutations relative to the FGFR4
(GenBank accession number
X57205)
e Single nucleotide polymorphism
(SNP)
f Gain-of-function mutations have
been demonstrated experimentally
g R612T is referred to as R496T in
the literature due to a numbering
relative to FGFR2 isoform 7
precursor which lacks two exons
compared with transcript variant 1
h Glu361 is only present in FGFR2
IIIb
i FGFR4 V550M, P712T and
S772N are referred to as V510M,
P672T and S732N (respectively) in
the literature and in COSMIC due
to a numbering relative to FGFR4
transcript variant 2, which lacks 40
amino acids (including the
transmembrane domain) compared
with X57205
FGFR Cancers Mutations References
FGFR1a Lung G70Re, T141Re, P252T/S, P576H, V664L [215, 216]
Prostate R78H [217]
Breast S125L [108, 218, 219]
Skin P252T/S [108, 217, 220]
Stomach A268S [217]
Colon A268S, A429S [217, 221]
Brain N546Kf, R576W, K656Ef [222]
FGFR2b Skin S24F, V77M, E160A, H213Y, E219K, G227E, V248D,
R251Q, G271E, G305R, T370R, W474X, E475K,
D530N, E574K, E636K, M640I, I642V, A648T, S688F,





Endometrial D101Y, S252Wf, P253Rf, K310R, A314D, A315T, S372C,
Y375C, C382R, A389T, M391R, I547, N549, K659/M/E
[115–117, 201, 224]
Breast R203C [108, 218, 225]
Lung N211I, D283, W290C, I380, H544Qe, R612Tg [108, 115, 201, 216,
220, 226]
Brain Q212, G462E [227, 228]
Ovary S252Wf, G272V, Y375C [229]
Stomach S267Pf [230]
Colon Q361Rh, P582L [228]
FGFR3c Lung T79S [108]
Multiple myeloma G197Se, Y241C, R248Cf, P250Re, Y373Cf, G380Rf,
G382Df, F384Le, S433C, A441Te, A452Se, K650E/Q/M/
N/Tf, A717Te, I726Fe
[137, 201, 231–239]
Colon C228R, E322 [108, 230]
Bladder R248C, S249C, G370C, S371C, Y373C, I376C, G380R,
G382D, F384Le, A391E, D646Y, K650E/Q/M/N/T
[120, 201, 240–250]
Head and neck R248Cf, S249Cf, D617G, V630, E686, G697Cf [251–253]
Cervix S249Cf [119, 254, 255]
Prostate S249Cf, F384Le, A391Ef [256]
Brain E466 [257]
Testis K650E/Q/M/N/Tf [258]
FGFR4d Rhabdomyosarcoma C56S, R72L, T122A, A175T, R234H, G388Re, N535/D,
V550Ef/L/Mi, A554, G576D
[259]
Lung R183Se, S232Ie, G388Re, R616Ge, E681, P712Tg,
A729Ge, S772
[108, 127, 201, 216,
217, 220, 260–
262]
Breast Y367Cf, G388Re, V550Ef/L/Ma [108, 124, 217, 218,
263]
Stomach G388Re [264]




Soft tissue sarcoma G388Re [267]
Prostate G388Re [217, 263, 268–271]
Head and neck G388Re [217, 272–274]
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carcinoma and endometrial carcinoma [115–117], sug-
gesting that point mutations which causes skeletal disor-
ders are also causally linked to tumorigenesis.
In addition, activating mutant forms of FGFR3 attrib-
uted to point mutations are frequently detected in bladder
cancer [118–120]. The substitution of cysteine residues at
the extracellular domain and juxtamembrane region
enhances intermolecular disulfide bonding and ligand-
independent receptor dimerization [121–123]. These events
eventually led to the continuous activation of FGFR3 and
its downstream signaling pathways.
FGFR4 G388R is one of the most common nucleotide
polymorphisms (SNPs), with at least one copy identified in
nearly 50 % of the population [124]. G388R sustains the
activation of FGFR4 [125], and human cancers character-
ized by this SNP were reported to be highly aggressive and
metastatic in nature [124, 126–129]. Additionally, the
FGFR4 R388 allele is also associated with invasion and
metastasis by stabilizing the endosomal MMP14, thus
promoting collagen degradation [126, 130]. The elevated
expression of MMP1 further stimulates the autophospho-
rylation of FGFR4 R388, and collectively these regulators
act synergistically to promote tumor invasion and metas-
tasis [126, 130].
Chromosomal translocation
Fusion proteins arise from intragenic chromosomal rear-
rangements that commonly involve reciprocal transloca-
tions. As a result of chromosomal fusions, the mutated
proteins gain new functions which dominate the functions
of wild-type proteins. Human FGFR fusion proteins gen-
erally consist of two main segments—the anterior being a
dimerized domain from a partnering gene and tyrosine
kinase domain at the posterior [131]. Unlike wild type
receptors, mutant FGFRs are expressed intracellularly and
retained in the cytosol, thus they escape the typical receptor
degradation processes, further prolonging the activation
signal [3].
FGFR-related fusion proteins which are caused by
intragenic chromosomal translocation have been detected
in hematological cancers (Table 4). These fusion proteins
are mainly found in patients diagnosed with stem cell
leukemia lymphoma (SCLL) (also known as 8p11 myelo-
proliferative) syndrome. FGFR fusion proteins are able to
transform normal cell lines into SCLL or chronic mye-
logenous leukemia-like disease (CMLL) [132–136]. Inter-
estingly, newly diagnosed multiple myeloma (MM)
patients that harbor the t(4;14) translocation often exhibit
overexpression of FGFR3 in the absence of activating
mutations, while late stage MM patients carrying the same
translocation were observed to have activated FGFR3 and
multiple myeloma SET domain (MMSET) mutations
[137]. It is believed that MMSET might contribute to
cellular adhesion, clonogenic growth, and tumorigenicity
[138]. The mechanism which drives the change in FGFR3
activation status during the early and late onset of MM has
yet to be elucidated. One plausible explanation is that other
forms of mutations that accompany FGFR3 translocation
may trigger and maintain the abnormal signaling of FGFR3
[137].
Addiction to FGF ligand via autocrine and paracrine
signalling
Soluble mitogenic growth factors can be synthesized by
one cell type and signals the proliferation of another cell
type, and the intersignaling between two different cells are
termed paracrine signaling [139]. Alternatively, cancer
cells may also produce growth factors to which they are
responsive, creating a positive feedback signaling loop
often termed autocrine stimulation [139].
One example of autocrine FGF-signaling is the elevated
expression of FGFR1 and its high-affinity ligand, FGF2 in
human melanoma xenografts. The silencing of either
FGFR1 or FGF2 arrests tumor growth, suggesting the
presence of the FGFR1–FGF2 autocrine loop in the subset
of human subcutaneous carcinomas [140]. Similarly, in
multiple basal-like breast cancer cells, tumor growth was
suppressed following RNAi-mediated silencing of endog-
enous FGF2 [141]. In human non-small-cell lung
Table 4 Fusion proteins of FGFRs found in human cancers




FOP/FGFR1OP1a SCLL [282–284], lung [285]
CEP110/CEP1a SCLL [284, 286–289]
BCR SCLL [136, 290–293]
LRRFIP1 SCLL [294]









FGFR3 TEL/ETV6a T-cell Lymphoma [305]
TACC3a Glioblastoma [303], bladder
[306]
a Fusion proteins which have been demonstrated to be functionally
oncogenic in cell lines and mouse models
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carcinomas (NSCLC), FGF2, FGF9, and their respective
receptors, were also reported to mediate autocrine signaling
which drives tumor resistance to specific kinase targeted
therapy [142].
Oncogenic transformation that is facilitated by paracrine
signaling is reflected in the formation of multifocal prostate
adenocarcinomas whereby FGF10, which is highly
expressed by mesenchymal cells, histologically transforms
and stimulates the expression of the epithelial androgen
receptor on the adjacent wild type epithelium [143]. In
addition, paracrine signaling of FGF10 promoted androgen
independent survival of a subset of prostate adenocarci-
noma, and also synergizes with epithelial autonomous
AKT signaling, leading to high-grade carcinoma [143].
FGF–FGFR paracrine signaling is also identified in a
subset of breast cancer stem-like cells. The uncontrolled
growth of this subpopulation was proposed to be driven by
estrogen hormone stimulation, which in turn, regulates the
paracrine signaling of FGF9–FGFR3 [144].
Impaired negative feedback mechanisms in FGFR
signaling
The deregulation of negative regulators of FGFR signaling
has been associated with the pathogenesis of various
malignancies. For instance, lack of SEF expression has
been observed in primary tumors of the breast, ovary, and
thyroid [145], while high-grade prostate carcinomas have
much lower SEF and SPRY expression compared to
healthy individuals [146, 147]. Consistent with this, the
levels of SEF is downregulated, whereas FGF2, FGF8, and
FGFR4 levels are upregulated in aggressive prostate cancer
specimens [148]. Taken together, these data imply that the
loss of SEF might contribute to the hyperactivation of the
FGF/FGFR signaling axis, thus leading to oncogenesis.
Localization of FGFRs to the surface of the plasma
membrane also facilitates FGF ligand binding and intra-
cellular tyrosine kinase transphosphorylation, an event
which is required to trigger signal transduction [149].
Under normal circumstances, ligand-receptor complexes
are usually endocytosed and transported to lysosomes for
degradation. Thus, disruption in the endocytic pathway is
expected to alter FGFR signaling [149, 150]. Indeed, in
patients suffering from achondroplasia (ACH) and related
chondrodysplasia, the substitution of K650E and G380R in
FGFR3 protects the surface growth-receptor from being
sorted to the lysosomes [151]. The accumulation of these
FGFR3 variants, in turn, boosts the signaling capacity of
the receptor as their retained half-life is twice that of the
wild-type receptor [151].
Similarly, the FGFR4 Arg388 SNP variant which is
found in most prostate cancer, has been reported not only
to protect FGFR from lysosomal degradation, but also to
sustain receptor phosphorylation [125]. Likewise, the
FGFR2 IIIb C3 variant which harbors nucleotide deletion
at the cytoplasmic C-terminal sequences known to code for
the endocytic motif, exhibited aberrant receptor trafficking
and stability, and thus, enhanced receptor signaling
capacity [152].
Alternative splicing of FGFRs
Alternative splicing of the IgIII (D3) domain generates the
IIIb and IIIc isoforms in FGFRs1–3 [142], and each of
these isoforms display different affinity to bind to their
FGF family members. For instance, FGFR1 IIIb, FGFR1
IIIc, and FGFR2 IIIc bind FGF2 and FGF9 with high
affinity, whereas FGFR2 IIIb preferably binds FGF7 and
FGF10 [142].
These IIIb and IIIc isoforms of FGFRs have different
roles in cancer. This is reflected in various cancers,
including breast, endometrial, cervical, lung, esophageal,
gastric, pancreatic, and colorectal cancer [153], which
displayed overexpression of FGFR2 IIIb. The role of
FGFR2 IIIb, together with its major ligands, such as FGF7
and FGF10, in this context, promotes tumor angiogenesis
and migration in pancreatic cancers [154, 155]. However,
the tumor promoting roles of FGFR2 IIIb is thought to be
exclusive to different cancer types. In line with this,
diminished expression of FGFR2 IIIb in gastric cancer cells
results in hyperproliferation and invasion [153, 156]. Fur-
thermore, cell lines derived from bladder cancers of lower
stage and grade expressed FGFR3 IIIb as their major
transcript, while cells derived from high grade tumors
exhibit a switch to favour FGFR3 IIIc expression, sug-
gesting that FGFR3 IIIb may have tumor-restrictive prop-
erties in bladder cancer [157]. These lines of evidence
imply that FGFR2 IIIb and FGFR IIIb play dual roles in
tumorigenesis.
Likewise, FGFR1 mRNA is exclusively spliced to
generate FGFR1 IIIc in small cell lung carcinoma
(NSCLC) cells lines [142]. Additionally, FGFR1 IIIc and
FGFR2 IIIc are frequently co-expressed with their com-
plementary ligands—FGF2 and FGF9 in primary NSCLC
tumors [142]. The role of IIIc and its respective ligands is
thought to compromise a growth factor autocrine loop in a
subset of NSCLC cells [142]. FGFR2 IIIc is also associated
with the progression of prostate cancers [158], and confers
growth advantage to cervical cancer cell lines [159].
Apart from the D3 domain variants, deregulated splicing
mechanism affecting other domains are also associated
with tumorigenesis. The increased expression of FGFR1b
isoform, which lacks the IgI domain, confers increased
sensitivity to FGF1, leading to poor prognosis in breast
tumors and malignant of astrocytomas [160]. Similarly, a
pituitary tumor-derived, N-terminally truncated isoform of
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FGF receptor-4 (ptd-FGFR4) which lacks the signal pep-
tide and the first two extracellular Ig-like domains, pos-
sesses high transforming properties in vitro and in vivo
[161]. The targeted expression of ptd-FGFR4 results in
pituitary tumors in transgenic mice [161].
In general, the alternative splicing of FGFRs generates
multiple isoforms, which are selectively expressed in dif-
ferent types of cancer. These isoforms have tumor pro-
moting and suppressive roles in different cancer types.
Further efforts to characterize the novel FGFRs isoforms,
and to determine if these isoforms antagonize, or work in
synergy to promote or repress cancer cell growth is nec-
essary to improve the design of cancer therapeutics.
Overall, the deregulation of FGFR can occur at several
tiers ranging from gene to protein translation and traffick-
ing, and that aberrant FGFR signaling is causally linked to
tumorigenesis.
Current targeted therapies for FGFRs/FGFs signaling
pathway
Given the important role of FGFR signaling in tumori-
genesis, various approaches have been developed to target
the upstream and downstream axis of this signaling path-
way. A number of novel therapeutic molecules have been
introduced and are currently undergoing preclinical and
clinical trials in various FGFRs-related tumors (Table 5).
These small molecules can be generally classified as
receptor tyrosine kinase inhibitors (RTKIs) which are
mainly ATP-competitive molecules; or antagonistic anti-
bodies which target FGF ligands or receptors [162].
Most of the RTKIs assessed to date are non-selective
FGFRs inhibitors. Despite targeting the FGFR family, they
also inhibit other RTKs such as vascular endothelial
growth factor receptors (VEGFRs) and platelet-derived
growth factor receptors (PDGFRs) [163, 164]. These
include compounds like the specific FGFR inhibitor,
PD173074; and second-generation FGFR inhibitors that
target FGFRs and other RTKs such as dovitinib (TKI258),
AZD4547, Ki23057, E7080, brivanib alaninate, intedanib,
ponatinib, MK-2461, and E-3810 [162]. Some of these
compounds, such as TKI258 and AZD4547 have demon-
strated promising potentials as inhibitors of FGFRs, are
being tested in advanced clinical trials.
Dovitinib shows high potency against most FGFRs
besides targeting c-KIT, CSF-1, VEGFRs and PDGFRs
(Table 5) [19, 165]. This molecule is currently being tested
in phase III clinical trial for renal cell carcinoma and phase
II clinical trials for advanced breast and endometrial can-
cers, relapsed MM, and urothelial cancer [162]. Given that
dovitinib may exert its anticancer effects either by directly
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cancer patients with or without FGFR2 mutations are
separately enrolled in a clinical to prove its mechanisms of
functions [166].
Unlike TKI258 which target multiple kinases, AZD4547
specifically targets FGFR family proteins. Pre-clinical
studies have recently demonstrated the selectivity and
potency of AZD4547 in FGFR-driven breast tumors cancer
models with minimal to none adverse drug reactions at
effective doses [167]. In addition, pre-clinical studies on
xenograft models transplanted with transformed cells
derived from FGFR1-amplified non-small cell lung cancer
(NSCLC) patients demonstrated that AZD4547 stops tumor
growth and promotes regression [168]. AZD4547 is cur-
rently under Phase II clinical trial for breast cancer and
phase I for solid tumors [162].
In addition to RTKIs, the development of therapeutic
monoclonal antibodies targeting the FGFRs signaling have
been demonstrated to exhibit specific antitumor activity in
cancer cell lines and animal models. For instance, KM1334
neutralizing antibodies targeting the FGF8 isoform b sig-
nificantly hinder FGF ligand-mediated signaling in mam-
mary tumorigenesis [169] and FGF8b-expressing clinical
prostate cancers [170] in addition to, inflammatory
responses and bone damages in rat model of rheumatoid
arthritis [169–171]. GP369, an isoform-specific blocking
antibody that binds to FGFR2 IIIb have been shown to
inhibit the proliferation of several human cancer cell lines
and tumor xenografts harboring FGFR2 gene amplification
and FGFR2 activating point mutation (S252W and N550K)
[99]. R3Mab, an antibody specifically acts on FGFR3 (IIIb
and IIIc isoforms) but has no effect on FGFR1, FGFR2, or
FGFR4 has been shown to exhibits significant inhibitory
effects on FGF1-induced cancer cell proliferation and
inhibitory effects on both bladder cancer and MM in mice
[172]. Several other antibodies such as IMC-A1 [173],
PRO-001 [174], R3Mab [172, 175] and 1A6 [176] also
show potentials in treating cancers driven by aberrant
FGFR signaling.
Another emerging treatment option is the FGF ligand
traps. FGF ligand trap is a fusion of Ig Fc with a soluble
FGFR construct that captures FGF1, 2, 3, 7, 10 and inhibits
ligand-dependent FGFR signaling [177]. One example of
this class of molecule which has been developed as cancer
therapeutics is FP-1039, which comprises of the extracel-
lular ligand-binding domain of FGFR1c fused to the
crystallizable fragment regions of human immunoglobulin
G [178, 179]. The specificity of this ligand is reflected by
the observation that the growth rate of head and neck
squamous cell carcinoma cells expressing abundant FGF2
is significantly inhibited upon treatment with FP-1039,
whereas HNSCC cells that express little FGF2 is not
affected [179]. FP-1039 is currently in a Phase II trial for
endometrial cancers with the S252W FGFR2 mutation
which confers increased affinity and altered specificity of
FGF binding [178].
Other strategies targeting the FGFR signaling such as
peptide mimetics, RNA aptamers, siRNAs and miRNAs
have also been investigated intensively merits further
improvements [180].
Challenges in the targeting FGFRs in human cancers
Given the broad expression of FGFRs and their key role in
development and physiology, toxicity issues are to be
expected from FGFR inhibition. The FGFR pathway is
involved in normal phosphate and vitamin D homeostasis.
The preclinical development of FGFR inhibitors has been
complicated by hyperphosphatemia-mediated tissue calci-
fication, due to the blockade of FGF23 release from bone
and of FGF23 signal in kidney [181]. In preclinical models,
dynamic modulation of circulating FGF23 levels was
reported following FGFR inhibition. FGF23 levels was
suppressed during the periods of drug exposure attributed
to direct inhibition of FGF23 release from the bone and
elevated upon drug withdrawal driven by increased plasma
phosphate and vitamin D levels acting on bone to stimulate
FGF23 production [182]. FGF23 may also bind FGFR4,
FGFR1 IIIc and FGFR3 IIIc [183, 184], but the relative
contribution of individual FGFR subtypes to hyperphos-
phatemia remains unclear [185–187].
Similarly, administration of an anti-FGFR1 IIIc anti-
body has been shown to result in profound weight loss in
preclinical in vivo models, potentially due to FGFR1 tar-
geting in the hypothalamus [173], and this has prevented
further clinical development. It remains to be ascertained
whether this would be a class effect for all FGFR1 IIIc
antibodies.
Finally, the great challenge for future development of
specific FGFR inhibitors in the clinic is to carefully
determine a therapeutic dose which will balance efficacy
against gene-addicted tumors with a manageable tolera-
bility profile. Continued clinical research may identify
which FGFR isoforms have the greatest efficacy potential,
and whether inhibition of particular isoforms can avoid
side effects associated with broad specificity small-mole-
cule FGFR inhibitors.
Conclusions
In conclusion, the role of FGFRs signaling in promoting
tumorigenesis is well established. As such, novel molecules
which inhibit FGF or FGFR interactions have been intro-
duced and many of them are currently undergoing clinical
trials for treating various types of human malignancies
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associated with hyperactivation of FGFR signaling. Given
that the standard chemotherapies in cancer patients are
often associated with adverse toxicity, such targeted-ther-
apies could present a more viable option in addressing this
issue. In addition, the inhibition of molecules downstream
of FGFRs network could also serve as a secondary
approach as many of these molecules regulate various
cellular processes and functions as well. With the emer-
gence of drug resistance and disease recurrence issues, the
current trend of clinical approach is moving towards multi-
targeted drugs and combination therapies. This requires in-
depth understanding of the signaling pathways in order to
formulate an appropriate strategy which focuses on cancer
cells. The clinical application of these therapeutic strate-
gies warrants further studies to ensure maximum clinical
benefit in cancer patients.
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